Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
about
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewA phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionOvarian cancer: opportunity for targeted therapy.Evaluation of a hypoxia regulated gene panel in ovarian cancer.Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessAnti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicityVascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.Profile of erlotinib and its potential in the treatment of advanced ovarian carcinomaInvestigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.Targeting tyrosine-kinases in ovarian cancer.The potential of sunitinib as a therapy in ovarian cancer.Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer.Emerging therapies: angiogenesis inhibitors for ovarian cancer.Prediction of therapy response in ovarian cancer: Where are we now?The rise of genomic profiling in ovarian cancer.
P2860
Q30248645-067857A1-9A33-4DD4-B6EC-7BE9799C816AQ33662162-08990C46-8A3D-47A8-A5A5-31A4BC267425Q34023223-4E68B107-C5F6-4F22-A530-BE3180034D20Q34916073-A09294FA-E570-495E-8662-0C3738E34E92Q35659945-163770BE-15DD-40B3-9A21-62DA00872BAEQ35666124-B277B8FC-0831-4C26-9A73-FCCF8BF47C63Q35921404-B842AD68-D68B-4CF6-9799-6CAA2A8026ACQ35954103-537C0598-2353-4E5B-B386-E075D50F570EQ36163297-0933E950-C87F-47C9-A7C1-DE0583A086A3Q36234132-84B37A2F-ACE0-4906-82EE-B1FA30174462Q36321894-41CDE5C7-3AF3-409E-9881-299E13DF2790Q36414088-E7E619DC-1E93-41F2-928F-31B43D901EF6Q36880902-2C738319-45BB-4F20-9937-A71B4A65A05BQ37705010-78F6492E-0817-48EB-97E3-905F5685DA4DQ38040628-0AE494E1-F360-4E01-884A-F85631EFDA31Q38115596-53A9A9BD-6E73-4713-8E59-8C6971AE8A48Q38118388-76EB080D-AF45-4AA8-910D-61BAAD67AC37Q38144166-0522AE78-4308-479A-BE19-479A98F05350Q38396441-E78C4FFC-FE5D-4E18-BE77-9694E7BBF4D7Q38497958-3B30DB2D-69F8-4EEE-965B-5306A59EFE04Q39263260-5B4C9826-7B56-453E-BE30-D4CB04C2639EQ50345037-9A8DA5EF-48E4-4E51-9401-B3E013DFF749
P2860
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@ast
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@en
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@nl
type
label
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@ast
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@en
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@nl
prefLabel
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@ast
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@en
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@nl
P2093
P2860
P921
P1476
Overexpression of tumor vascul ...... ib in resistant ovarian cancer
@en
P2093
Alan N Gordon
Amanda F Baker
David S Alberts
Denise J Roe
Haiyan Cui
Heather M Wright
Janice L Cohen
Jeffrey D Isaacs
Kenneth D Hatch
Mary C Clouser
P2860
P304
P356
10.1158/1078-0432.CCR-10-0974
P407
P577
2010-11-01T00:00:00Z